Resource Library
Burning Rock and Boehringer Ingelheim Achieved a Master Service Agreement in Oncology Companion Diagnostics
On October 25, 2023, during the 2023 Boehringer Ingelheim China R&D Day event, Burning Rock and Boehringer Ingelheim officially signed the Master Service Agreement (MSA) in the field of oncology companion diagnostics. This agreement aims...
Burning Rock Received Breakthrough Device Designation from China’s NMPA for its Multi-Cancer Early Detection Test
GUANGZHOU, China, Oct. 15, 2023 -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that followed an earlier Breakthrough Device Designation granted by the US...
Burning Rock announced a China collaboration with AstraZeneca
On August 9, 2023, Burning Rock (NASDAQ/LSE: BNR) announced a China collaboration with AstraZeneca (NASDAQ/LSE/STO: AZN). As part of the collaboration, Burning Rock will leverage its leading detection technologies and high-quality, standardized testing capabilities to develop...
Burning Rock Received FDA Breakthrough Device Designation for its OverC™ Multi-Cancer Detection Blood Test
IRVINE, Calif. Jan.03, 2023 - Burning Rock (NASDAQ/LSE: BNR), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its OverC™ Multi-Cancer Detection Blood...
Burning Rock Announces the Launch of China’s First Prospective Interventional Validation Study on Multi-Cancer Early Detection – the PREVENT Study
CHENGDU, China, June 30, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field...
Burning Rock Receives CE Mark Approval for Three NGS Tumor Kits
IRVINE, Calif. June 1, 2022--Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) announced that the Company had received CE mark approval for three self-developed next generation sequencing (NGS) kits, namely, “OncoScreen™ Plus...
Burning Rock Receives CE Mark for its OverC™ Multi-Cancer Detection Blood Test Kit
IRVINE, Calif. June 1, 2022--Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) announced that it has received CE marking for its OverC™ Multi-Cancer Detection Blood Test manufactured in both the US and...
Burning Rock Secures Second NGS Kit Approval from the NMPA
GUANGZHOU, China, March 15, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that the National Medical Products Administration (NMPA) approved Burning Rock’s Human Nine-Gene Mutation...
Merck KGaA, Darmstadt, Germany and Burning Rock Collaborate on Liquid-biopsy Based CDx Development Using Burning Rock’s OncoCompass™ Target
Burning Rock today announced a strategic partnership with Merck KGaA, Darmstadt, Germany, in companion diagnostics (CDx) development for the MET inhibitor tepotinib in the mainland China market. The CDx test is based on Burning Rock's...
Burning Rock and IMPACT Therapeutics Announce a Global Strategic Partnership for Companion Diagnostics Development
Guangzhou, China, August 3, 2021 – Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced a global strategic partnership with IMPACT Therapeutics in companion diagnostics (CDx) development for a pipeline...
Burning Rock Announces the Launch of China’s First Prospective Pan-Cancer Multi-omics Early Detection Study
BEIJING, May 19, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced the launch of the PRESCIENT (Pan-canceR Early-Stage deteCtion by lIquid Biopsy tEchNique projecT) study,...
Burning Rock and Abbisko Therapeutics Announce Strategic Partnership on Co-development of Companion Diagnostics for ABSK091
GUANGZHOU, China, April 29, 2021-- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”)today announced a strategic partnership with Abbisko Therapeutics (“Abbisko”) in companion diagnostics (CDx). The two companies will work together...
Burning Rock and CStone Pharmaceuticals reached a strategic collaboration on the co-development of companion diagnostics for pralsetinib in China
On June 29, 2020, Burning Rock Biotech Limited (NASDAQ: BNR) announced a strategic partnership with CStone Pharmaceuticals (HKEX: 2616) to co-develop and commercialize companion diagnostics (CDx) for pralsetinib, an investigational treatment developed by CStone’s partner...
Burning Rock deepens cooperation with Illumina to promote development and standardization of NGS-based cancer therapy selection [in China]
SHANGHAI, China, May 11, 2020-- Burning Rock and Illumina (NASDAQ: ILMN), a global leader in gene sequencing and array-based technologies, jointly announced today that they are joining forces to promote the development and standardization...
Burning Rock initiates the first prospective, multi-center pan-cancer early detection study in China
SHANGHAI, China, May 07, 2020 (GLOBE NEWSWIRE) -- Burning Rock today announces the initiation of its 14,000 patient PREDICT (Pan-CanceR Early DetectIon ProjeCT) study to further develop and validate its pan-cancer early detection technology. PREDICT...